Sito Epatite C
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Portale Epatite e malattie del fegato
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172) /ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION - EASL - The International Liver Congress 2015, 50th annual Meeting of the European association for the Study of the Liver Vienna, austria april 22-26

    2. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial - Jurgen K Rockstroh et al. - Lancet HIV 2015, Published Online July 10, 2015

    3. C-EDGE Co-Infected: final results from Phase 3 Study of elbasvir / grazoprevir in Patients with HCV/HIV - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 2015

    4. C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE - EASL - The International Liver Congress 2015, 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria April 22-26

    5. Efficacy and safety of MK-5172 + MK-8742± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hCV gT1 infection: The C-WORTHY study (Final results, Parts A and B) - 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 7-11 2014

    6. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial - Eric Lawitz et al. – The Lancet November 11, 2014

    7. C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR ± ELBASVIR ± RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5, OR 6 INFECTION - EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26

    8. EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED - EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria April 22-26

    9. Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent - Xavier Forns, et al. – Journal of Hepatology, S0168-8278(15)00291-3

    10. C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 2015

    11. Scheda tecnica ZEPATIER


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!